Biofarm posts net profit of 60 million RON, up 11 percent in 2021

Biofarm, one of the most important drug manufacturers in Romania, reports positive developments for the preliminary results of 2021: turnover of 239 million RON and a net profit of 60 million RON, up 11 percent compared to 2020. In addition, Biofarm reported EBITDA of 82 million RON, up 10 percent compared to 2020.

“Innovation, the driving force behind Biofarm’s mission, is strongly reflected in the figures for 2021, a year marked by significant achievements in all areas. The main events that defined Biofarm in 2021 were: the celebration of 100 years of uninterrupted activity, the inauguration of one of the most modern drug factories in Romania and the launch of Biofen Extra, through which we activated one of the most important CHC categories in terms of business potential,” said Cătălin Vicol, General Manager of Biofarm.

In terms of sell-out (sales from pharmacies to patients), Biofarm finished last year on the second position in terms of volume, respectively on the fourth position in terms of value in the category of CHC (Consumer Health Care). The launch of Biofen Extra consolidates Biofarm’s position in the top companies in the CHC category by activating one of the most important CHC categories in Romania – pain management. Biofen Extra, an OTC (Over-the-Counter) drug indicated in the treatment of severe pain, became a value leader in the ibuprofen and paracetamol combination segment within the first 8 months of its launch.